Skip to main content

Table 2 Characteristics of the patient population (n = 193).

From: Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: A cardiovascular magnetic resonance study

 

All patients

Absence of substantial viability

 

Substantial Viability

 
 

(n = 193)

All patients

(n = 86)

LVEF

< median

(n = 43)

LVEF

> median

(n = 43)

P1

(n = 107)

P2

Age, years

70 (63-75)

69 (59-76)

69 (61-76)

66 (59-76)

0.534

70 (65-75)

0.283

Male sex

167 (87%)

77 (90%)

37 (86%)

40 (93%)

0.291

90 (84%)

0.273

BMI (kg/m2)

28 (25-31)

27 (25-31)

29 (25-32)

26 (24-30)

0.111

28 (25-31)

0.773

Systolic blood pressure mmHg)

123 (111-140)

132 (110-148)

117 (102-145)

136 (123-149)

0.002

120 (111-134)

0.084

Diastolic blood pressure (mmHg)

73 (65-80)

74 (64-84)

72 (61-80)

74 (66-86)

0.296

72 (65-80)

0.641

Heart rate (bpm)

65 (59-75)

63 (58-70)

64 (58-74)

62 (57-68)

0.308

66 (59-76)

0.057

NYHA classification

    

0.022

 

0.357

NYHA class I

32 (17%)

12 (14%)

3 (14%)

9 (21%)

 

20 (19%)

 

NYHA class II

124 (64%)

60 (70%)

29 (67%)

31 (72%)

 

64 (60%)

 

NYHA class III

37 (19%)

14 (16%)

11 (26%)

3 (7%)

 

23 (21%)

 

Previous infarct

129 (67%)

62 (72%)

34 (79%)

28 (65%)

0.149

67 (63%)

0.165

Previous revascularisation

71 (37%)

29 (34%)

15 (35%)

14 (33%)

0.820

42 (40%)

0.428

Co-morbidities:

       

History of hypertension

56 (29%)

24 (28%)

10 (23%)

14 (33%)

0.336

32 (30%)

0.761

Diabetes mellitus

36 (19%)

13 (15%)

5 (12%)

8 (19%)

0.366

23 (22%)

0.258

Medications:

       

β-blockers

167 (87%)

82 (95%)

42 (98%)

40 (93%)

0.306

85 (79%)

0.001

RAAS inhibitors

175 (91%)

83 (97%)

41 (95%)

42 (98%)

0.557

92 (86%)

0.012

Diuretics

130 (67%)

55 (64%)

30 (70%)

25 (58%)

0.261

75 (70%)

0.366

Spironolactone

53 (28%)

21 (24%)

16 (37%)

5 (12%)

0.006

32 (30%)

0.396

Digoxin

18 (9%)

6 (7%)

4 (9%)

2 (5%)

0.397

12 (10%)

0.314

CMR measurements

       

LVEF

34 (27-43)

41 (29-51)

29 (24-38)

50 (45-57)

 

31 (24-35)

< 0.0001

LVEDV index

117 (95-150)

103 (84-127)

126 (101-155)

91 (69-104)

< 0.0001

129 (111-156)

< 0.0001

LVESV index

78 (55-110)

57 (41-83)

82 (69-113)

42 (32-54)

< 0.0001

89 (72-117)

< 0.0001

LVMM index

82 (71-101)

80 (68-97)

91 (73-106)

75 (65-84)

0.002

85 (74-101)

0.120

Segmental analysis

       

Segments

3281

1462

731

731

 

1819

 

Dysfunctional Segments

1759 (53%)

527 (36%)

154 (21%)

373 (51%)

< 0.0001

1232 (68%)

 

Dysfunctional segments without LGE

581 (18%)

31 (2%)

14 (2%)

17 (2%)

0.884

550 (30%)

 

Dysfunctional segments with LGE

1178 (36%)

496 (34%)

140 (19%)

356 (49%)

< 0.0001

682 (37%)

 

Dysfunctional segments with > 50% LGE

559 (17%)

313 (21%)

65 (9%)

248 (34%)

< 0.0001

246 (14%)

 

Segments with normal function - no LGE

1326 (40%)

849 (58%)

513 (70%)

336 (46%)

< 0.0001

477 (26%)

 

Segments with normal function and LGE

98 (3%)

43 (3%)

32 (4%)

11 (2%)

0.283

55 (3%)

 
  1. Data are expressed as median and interquartile range (IQR) or as number and percentage (%) of patients.
  2. P 1 value represents the significance of differences between the subgroups of patients with no substantial viability and LVEF > median (41%) and those with LVEF < median
  3. P 2 value expresses comparison between the groups with significant viability and no significant viability
  4. LV, left ventricular; EF, ejection fraction; BMI, body mass index; NYHA, New York Heart Association; RAAS, rennin-angiotensin-aldosterone system; EDV, end-diastolic volume; ESV, end-systolic volume; MM, myocardial mass; LGE, late gadolinium enhancement.
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us